Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)

Andrew Horti, Yongjun Gao, Hayden T. Ravert, Paige Finley, Heather Valentine, Dean Foster Wong, Christopher J. Endres, Alena Savonenko, Robert F Dannals

Research output: Contribution to journalArticle

Abstract

Recently, A-836339 [2,2,3,3-tetramethylcyclopropanecarboxylic acid [3-(2-methoxyethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]amide] (1) was reported to be a selective CB2 agonist with high binding affinity. Here we describe the radiosynthesis of [11C]A-836339 ([11C]1) via its desmethyl precursor as a candidate radioligand for imaging CB2 receptors with positron-emission tomography (PET). Whole body and the regional brain distribution of [11C]1 in control CD1 mice demonstrated that this radioligand exhibits specific uptake in the CB2-rich spleen and little specific in vivo binding in the control mouse brain. However, [ 11C]1 shows specific cerebral uptake in the lipopolysaccharide (LPS)-induced mouse model of neuroinflammation and in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's disease (APPswe/PS1dE9 mice). These data establish a proof of principle that CB 2 receptors binding in the neuroinflammation and related disorders can be measured in vivo.

Original languageEnglish (US)
Pages (from-to)5202-5207
Number of pages6
JournalBioorganic and Medicinal Chemistry
Volume18
Issue number14
DOIs
StatePublished - Jul 15 2010

Fingerprint

Cannabinoid Receptor CB2
Positron emission tomography
Cannabinoids
Positron-Emission Tomography
Brain
Imaging techniques
Amyloid
Amides
Lipopolysaccharides
Amyloid Plaques
Alzheimer Disease
Spleen

Keywords

  • Alzheimer's disease
  • Cannabinoid receptor
  • CB receptor
  • Neuroinflammation
  • PET
  • Positron-emission tomography

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry
  • Medicine(all)

Cite this

Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). / Horti, Andrew; Gao, Yongjun; Ravert, Hayden T.; Finley, Paige; Valentine, Heather; Wong, Dean Foster; Endres, Christopher J.; Savonenko, Alena; Dannals, Robert F.

In: Bioorganic and Medicinal Chemistry, Vol. 18, No. 14, 15.07.2010, p. 5202-5207.

Research output: Contribution to journalArticle

@article{e20e65f29bc3447591e129ce8fe7b04f,
title = "Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)",
abstract = "Recently, A-836339 [2,2,3,3-tetramethylcyclopropanecarboxylic acid [3-(2-methoxyethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]amide] (1) was reported to be a selective CB2 agonist with high binding affinity. Here we describe the radiosynthesis of [11C]A-836339 ([11C]1) via its desmethyl precursor as a candidate radioligand for imaging CB2 receptors with positron-emission tomography (PET). Whole body and the regional brain distribution of [11C]1 in control CD1 mice demonstrated that this radioligand exhibits specific uptake in the CB2-rich spleen and little specific in vivo binding in the control mouse brain. However, [ 11C]1 shows specific cerebral uptake in the lipopolysaccharide (LPS)-induced mouse model of neuroinflammation and in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's disease (APPswe/PS1dE9 mice). These data establish a proof of principle that CB 2 receptors binding in the neuroinflammation and related disorders can be measured in vivo.",
keywords = "Alzheimer's disease, Cannabinoid receptor, CB receptor, Neuroinflammation, PET, Positron-emission tomography",
author = "Andrew Horti and Yongjun Gao and Ravert, {Hayden T.} and Paige Finley and Heather Valentine and Wong, {Dean Foster} and Endres, {Christopher J.} and Alena Savonenko and Dannals, {Robert F}",
year = "2010",
month = "7",
day = "15",
doi = "10.1016/j.bmc.2010.05.058",
language = "English (US)",
volume = "18",
pages = "5202--5207",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2)

AU - Horti, Andrew

AU - Gao, Yongjun

AU - Ravert, Hayden T.

AU - Finley, Paige

AU - Valentine, Heather

AU - Wong, Dean Foster

AU - Endres, Christopher J.

AU - Savonenko, Alena

AU - Dannals, Robert F

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Recently, A-836339 [2,2,3,3-tetramethylcyclopropanecarboxylic acid [3-(2-methoxyethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]amide] (1) was reported to be a selective CB2 agonist with high binding affinity. Here we describe the radiosynthesis of [11C]A-836339 ([11C]1) via its desmethyl precursor as a candidate radioligand for imaging CB2 receptors with positron-emission tomography (PET). Whole body and the regional brain distribution of [11C]1 in control CD1 mice demonstrated that this radioligand exhibits specific uptake in the CB2-rich spleen and little specific in vivo binding in the control mouse brain. However, [ 11C]1 shows specific cerebral uptake in the lipopolysaccharide (LPS)-induced mouse model of neuroinflammation and in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's disease (APPswe/PS1dE9 mice). These data establish a proof of principle that CB 2 receptors binding in the neuroinflammation and related disorders can be measured in vivo.

AB - Recently, A-836339 [2,2,3,3-tetramethylcyclopropanecarboxylic acid [3-(2-methoxyethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]amide] (1) was reported to be a selective CB2 agonist with high binding affinity. Here we describe the radiosynthesis of [11C]A-836339 ([11C]1) via its desmethyl precursor as a candidate radioligand for imaging CB2 receptors with positron-emission tomography (PET). Whole body and the regional brain distribution of [11C]1 in control CD1 mice demonstrated that this radioligand exhibits specific uptake in the CB2-rich spleen and little specific in vivo binding in the control mouse brain. However, [ 11C]1 shows specific cerebral uptake in the lipopolysaccharide (LPS)-induced mouse model of neuroinflammation and in the brain areas with Aβ amyloid plaque deposition in a mouse model of Alzheimer's disease (APPswe/PS1dE9 mice). These data establish a proof of principle that CB 2 receptors binding in the neuroinflammation and related disorders can be measured in vivo.

KW - Alzheimer's disease

KW - Cannabinoid receptor

KW - CB receptor

KW - Neuroinflammation

KW - PET

KW - Positron-emission tomography

UR - http://www.scopus.com/inward/record.url?scp=77955323562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955323562&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2010.05.058

DO - 10.1016/j.bmc.2010.05.058

M3 - Article

C2 - 20554448

AN - SCOPUS:77955323562

VL - 18

SP - 5202

EP - 5207

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 14

ER -